

John W. Ludlow, Ph.D, is the Principal at JWLudlow Consulting, LLC (Chapel Hill, NC). He is currently serving as Vice President, Regenerative Medicine, at Zen Bio Inc. (Durham, NC) and Chief Scientific Officer at Brite Bio Inc. (Durham, NC). Prior to becoming a consultant in 2012, John was Senior Director, Process Research and Assay Development at Tengion Inc., a tissue engineering and regenerative medicine company located in Winston-Salem, NC. He held this position for 7 years. John has also served as Senior Director, Cell Therapy Program, Vesta Therapeutics, Inc., (formerly Incara Pharmaceuticals) in Research Triangle Park, NC, for 5 years. John has both developed and managed research and pre-clinical programs, initiated clinical trial sites, and directed development activities for cell therapy and tissue engineered products. He is an inventor on 4 issued patents pertaining to regenerative medicine products, and has published over 100 articles. Working closely with regulatory agencies, John has helped to ensure approval of the company's products. He began his career as a faculty member at the University of Rochester Cancer Center (Rochester, NY), where for 10 years he maintained an independently funded research laboratory training graduate students and post-doctoral fellows in the area of tumor suppressor gene expression, protein structure, and function. John received his Ph.D in Microbiology, with an emphasis in virology, from Kansas State University (Manhattan, KS) in 1987. He followed this with postdoctoral training at Harvard Medical School and Dana-Farber Cancer Institute (Boston, MA) in the area of tumor biology.